The US Food and Drug Administration (FDA) has approved Joenja (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older, Dutch biotech firm Pharming (Euronext: PHARM) announced late Friday.
The FDA nod, which came a few days ahead of the March 29 action date, sent Pharming’s US traded shares soaring 33%, to end the day at $14.96.
Joenja, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the USA for APDS, a rare and progressive primary immunodeficiency.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze